Korean Govt to Temporarily Exempt Tamiflu, Relenza from Tariffs; Green Cross Begins H1N1 Clinical Trials
This article was originally published in PharmAsia News
Executive Summary
SEOUL - The Korean government will temporarily exempt Roche's Tamiflu (oseltamivir) and GlaxoSmithKline's Relenza (zanamivir) from a tariff and a local value-added tax until the end of next year as part of an effort to help local A/H1N1 flu patients get fast and easy access to treatments at lower costs
You may also be interested in...
Korea's Green Cross in Talks with MNCs Over A/H1N1 Vaccine Adjuvants
SEOUL - Amid rising concerns that the government may have to import substantial doses of an A/H1N1 flu vaccine soon from other countries, including China, South Korean vaccine maker Green Cross said it is currently in talks with multinational companies to buy the adjuvants used in production of the flu vaccine
Roche, GSK Face Compulsory Licensing Of Antivirals If Swine Flu Emergency Hits - South Korean Health Minister
SEOUL - Roche's Tamiflu (oseltamivir) and GlaxoSmithKline's Relenza (zanamivir) could be manufactured under compulsory licensing in South Korea if the country faces an emergency swine flu threat in the coming months, Health, Welfare and Family Affairs Minister Jeon Jae-Hee said
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).